For a patient with PSMA+ mCRPC but relatively low SUV values, does that influence your decision to use 177Lu-PSMA or discussion with patient regarding potential benefit?

In general, the use of PSMA-lutetium is primarily utilized in patients with advanced metastatic castration resistant prostate cancer which has been heavily pre-treated with at least one novel anti-androgen (and often several) and one or two taxane based therapies.

No prospective trial has addressed ...